| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
29,731 |
29,384 |
$1.37M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
13,634 |
11,265 |
$749K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,192 |
17,546 |
$537K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,631 |
3,245 |
$360K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,224 |
2,203 |
$286K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,149 |
4,027 |
$147K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,377 |
3,103 |
$85K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
6,029 |
4,585 |
$66K |
| 99000 |
|
22,508 |
21,215 |
$57K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,998 |
2,047 |
$56K |
| 87631 |
|
99 |
95 |
$9K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
32 |
31 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
155 |
154 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
77 |
72 |
$2K |
| 94060 |
|
51 |
44 |
$2K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
15 |
14 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
145 |
141 |
$2K |
| 81025 |
|
370 |
350 |
$932.18 |
| 81003 |
|
340 |
329 |
$810.42 |
| 71046 |
Radiologic examination, chest; 2 views |
41 |
39 |
$786.40 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
15 |
14 |
$600.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
31 |
31 |
$577.83 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
32 |
29 |
$556.76 |
| 81002 |
|
273 |
264 |
$460.25 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
24 |
24 |
$362.91 |
| 81005 |
|
165 |
149 |
$242.76 |